Drugnews

How did Lilly grow Q3 2026 revenue while realised prices fell?

On October 29, 2026, Eli Lilly reported Q3 2026 revenue of US$24.40 billion, up 39% year over year, as worldwide volume grew 53% while realised prices fell 15%. Drugnews’s November 2, 2026 analysis attributes the reported growth mainly to the volume expansion around Mounjaro and Zepbound, both tirzepatide brands.

Updated

Lilly worldwide Q3 2026 results
MeasureReported resultBasis
RevenueUS$24.40 billionReported quarterly revenue
Revenue growth39%Year over year
Volume growth53%Worldwide
Realised price decline15%Worldwide

The reported growth components should not be treated as a simple multiplication of aggregate price and volume percentages.

Sources

Read the full analysis

Lilly Cut Obesity Drug Prices 15% and Grew 39% — 2026-11-02